Licensed for the treatment of insomnia in children and adolescents aged 2 to 18 years with Autism Spectrum Disorder (ASD) and/or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient - more information.
Tablet Has potential to cause tolerance, dependence and withdrawal symptoms, and is liable to abuse.Licensed for short-term use only (4 weeks). Maximum daily dose (adults) is 7.5mg at night Do not crush zopiclone tablets (they are difficult to crush, taste very bitter and the bioavailability may be affected)- more information
Mixture and Solution - unlicensed For paediatric use only
Sodium Oxybate (Xyrem®)
Oral solution NHS England will commission sodium oxybate for symptom control of narcolepsy with cataplexy (children) in accordance with the criteria outlined below. Patients in secondary care should be referred to the designated tertiary service
The safety and efficacy of both formulations in children and adolescents aged 0 – 18 years has not been established and should not be used in this age group - more information.
Melatonin (Pharm Nord)
Short-term treatment of jet-lag in adults.
No formal assessment
- no formal assessment
Tablet, Oral Suspension
Triclofos Sodium (Triclofos® oral Solution BP (Triclofos Elixir))
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Medicines that should be initiated by a specialist and prescribed by primary care prescribers only under a shared care protocol. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred.
Medicines suitable to be prescribed in primary care after specialist recommendation or initiation
This will signify a product that is approved for initiation in either primary or secondary care within licensed indications.
Specialist initiation and shared care guidelines are not considered necessary.
Medicines restricted for use in those patients under the care of external trusts i.e
- Peterborough and Stamford Hospitals NHS Foundation Trust or the Northern Lincolnshire and Goole NHS Foundation Trust
This will signify that a product has been approved for use within secondary or tertiary care, or by a primary care hosted specialist service
only and should not be routinely prescribed in primary care. RED drugs may be used within ULHT or LPFT subject to approval for use
within each trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their trusts. RED classification
does not automatically signify that a drug will be available within secondary/tertiary care.
This will signify that a product is not recommended for prescribing in both primary and secondary care. All new
products are classified as RED-RED pending assessment by PACEF.